Mela Sciences pulls in funding to fuel reimbursement push for melanoma Dx device

Mela Sciences has raised $27.3 million in new financing to help it win reimbursement and pursue more clinical testing for its MelaFind system, which has U.S. and EU approval to help dermatologists diagnose melanoma.

Quest's Q2 revenue dips as it absorbs restructuring and M&A expenses

Quest Diagnostics saw its net income drop and earnings per share decline during the 2014 second quarter, as the company absorbed costs stemming from restructuring and M&A integration expenses. The New Jersey diagnostics giant has also adjusted full-year revenue projections for 2014.

Quest forks over milestone payments to French Dx company in development deal

Quest Diagnostics' partnership deal with a state-of-the-art French company is showing signs of paying off.

A missile, a plane crash and a profound loss to AIDS research

Unfortunately, the biggest news coming out of the 20th International AIDS Conference involves the researchers who were killed on their way there.

GeneCentric grabs $5M Series A to advance testing for personalized cancer treatments

Startup GeneCentric Diagnostics pulled in $5 million in new Series A financing, according to reports from The Herald-Sun and Dow Jones VentureWire, among other media organizations. The money will help the North Carolina startup advance further development of gene-based diagnostic products designed to enable personalized treatments.

PA startup's Series B will bring arthroscopic Dx needle through FDA clearance and launch

A three-year-old Pennsylvania startup pulled in the first tranche of a $11.6 million financing designed to help bring its first needle-based, minimally invasive diagnostic tool through regulatory clearance and commercial launch.

AIDS 2014: Norway's Bionor produces possible biomarker to predict HIV vaccine effectiveness

Norway's Bionor Pharma and U.K. scientists claim they've identified a biomarker in some patients that may be connected with an improved response to a therapeutic HIV vaccine now under development.

Foundation Medicine scores with new regulatory approvals for two Dx tests

Revenue isn't yet growing fast enough for cancer diagnostics darling Foundation Medicine, making the recent New York State Department of Health approval of the Massachusetts company's two initial cancer tests all the more significant.

Abbott's Dx arm chugs along in Q2

Abbott Laboratories reported solid sales gains in its core laboratory and point-of-care diagnostics lines during the 2014 second quarter, thanks to larger testing volumes and new products.

NeuroVision Imaging's CEO discloses approval timeline for eye test to help spot Alzheimer's

NeuroVision Imaging recently reported positive early results from a clinical trial using a digital eye-imaging diagnostic designed to help detect Alzheimer's related symptoms such as retinal plaque.

MGC Diagnostics grows international reach with Belgian M&A deal

MGC Diagnostics continues its reinvention in 2014 with an eye on overseas growth. The Minnesota cardiorespiratory medical diagnostics outfit said it expects to complete the acquisition of a Belgian competitor by Aug. 1.

Roche and Merck KGaA team on a multicancer companion diagnostic test

Roche's Ventana Medical Systems will develop a companion diagnostic test with Germany's Merck KGaA that can be used for many different cancer types.

Asuragen gains New York's OK to launch autism and thyroid tests

Asuragen gained approval to start offering two of its key molecular diagnostic tests in New York state, milestones that will help boost the standard of care and give the Texas company another opportunity to grow its market reach.

Maryland researchers expand usefulness of schizophrenia biomarker found in saliva

A biomarker previously linked with schizophrenia and found in saliva seems to say more nuanced things about the disease than previously thought, based on a new study that involved computer stress tests.

French Dx outfit bioMérieux begins $48M expansion effort in North Carolina

The Triangle Business Journal reported that the company will add a 25,500-square-foot addition to its existing facility, to produce products needed to help diagnose clinical sepsis.

U.K. company readies jump into bustling prenatal Dx market

A U.K. company aims to become the latest player in an already-packed prenatal diagnostics market, with plans to launch its first test in the European Union and Asia.

Proteome Sciences, U.K. academics spot 10 Alzheimer's predictive biomarkers in blood

U.K. researchers from academia and industry say they've taken a big step forward in developing a viable Alzheimer's blood test. The advance is this: the discovery of 10 protein biomarkers in the blood that they assert can help predict the onset of the neurodegenerative disease.

With funding secured, Definiens CEO Heydler talks about hoped-for digital tissue Dx boom

In the wake of new venutre funding, FierceDiagnostics asked the CEO of tissue diagnostics comapny Definiens what will come next. The answer involves a range of bullish projections and enormous expectations.

UC San Diego biomarker discovery could boost brain cancer drug's success rate

Researchers in California believe they've zeroed in on biomarkers--microRNAs--that will help determine who will respond best to the treatment and help boost its success rate.

NIH gives Kansas City startup $3M to come up with a quicker sepsis Dx test

A Kansas City startup nailed down $3 million in grant money from the National Institutes of Health to develop a diagnostic test that screens for sepsis more quickly than possible under current standards of care.